Follow
Mehdi Touat
Mehdi Touat
Sorbonne-Universités & Dana-Farber Cancer Institute
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
Targeting FGFR signaling in cancer
M Touat, E Ileana, S Postel-Vinay, F André, JC Soria
Clinical cancer research 21 (12), 2684-2694, 2015
5202015
Mechanisms and therapeutic implications of hypermutation in gliomas
M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ...
Nature 580 (7804), 517-523, 2020
4662020
Glioblastoma targeted therapy: updated approaches from recent biological insights
M Touat, A Idbaih, M Sanson, KL Ligon
Annals of Oncology 28 (7), 1457-1472, 2017
4032017
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
M Touat, T Maisonobe, S Knauss, O Ben Hadj Salem, B Hervier, K Auré, ...
Neurology 91 (10), e985-e994, 2018
3122018
BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study
T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ...
Journal of Clinical Oncology 36 (35), 3477, 2018
3012018
Detection, characterization, and inhibition of FGFR–TACC fusions in IDH wild-type glioma
AL Di Stefano, A Fucci, V Frattini, M Labussiere, K Mokhtari, P Zoppoli, ...
Clinical cancer research 21 (14), 3307-3317, 2015
2562015
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
J Mondesir, C Willekens, M Touat, S de Botton
Journal of blood medicine, 171-180, 2016
2452016
Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma
IK Mellinghoff, BM Ellingson, M Touat, E Maher, MI De La Fuente, ...
Journal of clinical oncology 38 (29), 3398-3406, 2020
2102020
Neurological toxicities associated with immune-checkpoint inhibitors
M Touat, D Talmasov, D Ricard, D Psimaras
Current opinion in neurology 30 (6), 659-668, 2017
1902017
Vorasidenib in IDH1-or IDH2-mutant low-grade glioma
IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ...
New England Journal of Medicine 389 (7), 589-601, 2023
1552023
Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial
PY Wen, M Touat, BM Alexander, IK Mellinghoff, S Ramkissoon, ...
Journal of clinical oncology 37 (9), 741, 2019
1482019
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
RV Lukas, J Rodon, K Becker, ET Wong, K Shih, M Touat, M Fassò, ...
Journal of neuro-oncology 140, 317-328, 2018
1382018
Emerging circulating biomarkers in glioblastoma: promises and challenges
M Touat, A Duran-Peña, A Alentorn, L Lacroix, C Massard, A Idbaih
Expert review of molecular diagnostics 15 (10), 1311-1323, 2015
832015
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
H Vallet, A Gaillet, N Weiss, C Vanhaecke, S Saheb, V Touitou, N Franck, ...
Annals of Oncology 27 (7), 1352-1353, 2016
792016
Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)
M Touat, G Lombardi, P Farina, M Kalamarides, M Sanson
Acta neurochirurgica 156, 1831-1835, 2014
662014
FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas
A Picca, G Berzero, F Bielle, M Touat, J Savatovsky, M Polivka, E Trisolini, ...
Neurology 90 (23), e2086-e2094, 2018
612018
PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited
S Knauss, C Preusse, Y Allenbach, S Leonard-Louis, M Touat, N Fischer, ...
Neurology: Neuroimmunology & Neuroinflammation 6 (3), e558, 2019
542019
Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade
IF Dunn, Z Du, M Touat, MB Sisti, PY Wen, R Umeton, AM Dubuc, ...
JCO precision oncology 2, 2018
522018
Performance of next-generation sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair
T Ratovomanana, R Cohen, M Svrcek, F Renaud, P Cervera, A Siret, ...
Gastroenterology 161 (3), 814-826. e7, 2021
492021
ACTR-46. AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: updated results from the phase 1 non-enhancing glioma …
IK Mellinghoff, M Touat, E Maher, M De La Fuente, TF Cloughesy, ...
Neuro-Oncology 19 (suppl_6), vi10-vi11, 2017
492017
The system can't perform the operation now. Try again later.
Articles 1–20